Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD: Beyond the Nomenclature, Part 1

Description

Presenters in this 2-part session dissect the intricate relationship between metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlapping entity MetALD. Renowned experts explore these entities in terms of epidemiology, etiology, clinical diagnostics, and therapeutic approaches. Presenters delve into whether these conditions are distinct, overlapping, or part of a disease continuum by scrutinizing molecular, histologic, and epidemiologic evidence, and discuss future directions in screening, stratification, and drug development. Join this session to: (1) gain insights into the nuances that differentiate MASLD, ALD, and MetALD and the evidence supporting a spectrum or continuum of disease; (2) expand knowledge to apply advanced diagnostic tools effectively in clinical practice; (3) hone diagnostic and therapeutic strategies; and (4) develop a deeper understanding of the treatment landscape, unmet needs, and future directions in therapy and research for these liver diseases.
 

Journey Maps

Presentations

8:00 AM - 8:15 AM
Nov 16 2024
San Diego, CA

Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD: Three Different Entities or Overlap and Continuation?

Norah Terrault, MD, MPH, FAASLD, Presenter
ALD
MASLD
8:15 AM - 8:30 AM
Nov 16 2024
San Diego, CA

Molecular Evidence for the Three Entities

Anna Mae Diehl, MD, FAASLD, Presenter
ALD
MASLD
8:30 AM - 8:45 AM
Nov 16 2024
San Diego, CA

Histologic Evidence for Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD

Cindy A Behling, MD, Ph.D, Presenter
ALD
MASLD
8:45 AM - 9:00 AM
Nov 16 2024
San Diego, CA

Screening and Stratifying in Metabolic Dysfunction-Associated Steatotic Liver Disease Versus Alcohol-Associated Liver Disease Versus MetALD

Luis Antonio Diaz, MD, Presenter
ALD
MASLD
9:00 AM - 9:30 AM
Nov 16 2024
San Diego, CA

Panel Discussion

Alina M. Allen, MD, Moderator
ALD
MASLD

Objectives

  • Describe the distinctions and potential overlaps in the prevalence, progression, and outcomes of MASLD, ALD, and MetALD.
  • Discuss the current and emerging diagnostic modalities used to distinguish between MASLD, ALD, and MetALD, particularly in the context of use of AI to enhance histologic interpretation.
  • Review the impact of therapeutic interventionsspecifically those targeting the gut-liver axis and metabolic pathways in MASLD and MetALDand the design and outcomes of clinical trials in this domain.
Chair

Juan Pablo Arab, MD, FRCPC

Virginia Commonwealth University
Chair

Alina M. Allen, MD

Mayo Clinic Rochester